Zevra Therapeutics Inc. (ZVRA)

Zevra Therapeutics Inc. (ZVRA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $676M; returns 1 day -5.0%, 1 week -1.3%, 1 year -8.1%.

Zevra Therapeutics Inc. (ZVRA) is a commercial-stage company focused on acquiring, developing, and commercializing therapies for rare diseases with limited or no treatment options. Zevra's portfolio includes MIPLYFFA, FDA-approved for Niemann-Pick disease type C (NPC), OLPRUVA for Urea Cycle Disorders (UCDs), and AZSTARYS licensed for ADHD.

Groups ZVRA belongs to

• Rare Diseases
• Biotechnology
• Healthcare
• Commercial Stage Biotech
• Pharmaceuticals
• Unmet Medical Needs
• Biopharmaceutical
• Commercial Stage
• Life Sciences
• Neurological Disorders
• Metabolic Disorders

ZVRA financial model: income statement, cash flow and balance sheet